Analysts suggest investing in KIMS, Endurance Tech, KPIL, Godfrey Phillips, and Senco Gold for potential growth across healthcare, automotive, infrastructure, FMCG, and retail sectors. The suggested target prices are Rs 888 (KIMS), Rs 2,830 (Endurance), Rs 1,400 (KPIL), Rs 2,700 (Godfrey Phillips), and Rs 450 (Senco Gold) with stop-loss levels defined.

KIMS Hospitals reported a 35.3% year-on-year increase in Q4 revenue to ₹1,084 crore, with a 19.9% EBITDA margin. Despite this growth, profit after tax (PAT) decreased due to expansion costs. The new units played a significant role in the overall FY26 revenue growth of 28.2%.

Investment firm Prabhudas Lilladher continues to recommend buying shares in Krishna Institute of Medical Sciences (KIMS), with a target price of Rs 800. This optimistic stance is based on KIMS' projected EBITDA Compound Annual Growth Rate (CAGR) of 32% from FY26 to FY28, despite a potential 7-10% decrease in Profit After Tax (PAT) due to increased depreciation and interest expenses.

Emkay reaffirms its positive stance on Krishna Institute of Medical Sciences, setting a new price target at ₹825. This revision indicates a potential increase of around 15% compared to the previous target.

Goldman Sachs maintains a positive outlook for KIMS, recommending investors to buy and predicting a potential price of ₹1,025.

The shares of Krishna Institute of Medical Sciences (KIMS) have surged to Rs 761.6, suggesting a strong uptrend with increasingly higher highs and lows according to technical analysis. This positive momentum could indicate a promising future for the stock.

KIMS' Q4 net profit declined by 58% year-on-year, reaching ₹425 million, while revenue significantly increased by 34%, hitting ₹10.7 billion. Notably, the EBITDA margin decreased to 19.2%.

The Krishna Institute of Medical Sciences (KIMS) has experienced a technical breakthrough, surpassing the ₹770 mark. Analysts predict further growth up to ₹820, given its current PE ratio of 35x.

Krishna Institute of Medical Sciences reported a Q4 EBITDA increase to ₹2 billion, up from ₹1.98 billion year-over-year, but margins dipped significantly to 19.2%, down from 24.85%.

Krishna Institute of Medical Sciences has released their Q4 financial results, providing insights into their recent performance in the healthcare sector. Investors and stakeholders are encouraged to review these figures for a comprehensive understanding of the institute's progress.

Vodafone Idea shares have surged, making it an attractive choice for investors. Simultaneously, Tata Consumer Products' strong performance is worthy of consideration. Meanwhile, Rain Industries, Advanced Enzymes, Vijaya Diagnostics, and KIMS are gaining attention as potential buy opportunities.

KIMS has agreed to a 60-year lease with APCRDA for a new hospital project in Amaravati, expanding its footprint. However, the company's Q3 profit saw a significant decline of 39.8%, despite a 29.2% revenue growth, highlighting some operational challenges.

Krishna Institute of Medical Sciences (KIMS) experienced a significant 7.3% increase, reaching Rs 764.3, outperforming the Sensex's 1.1% decline. This surge can be attributed to a newly inked hospital lease deal and the stock trading above crucial averages, resulting in a year-to-date return of 26.8%.

Krishna Institute of Medical Sciences has acquired a 2-acre plot in Andhra Pradesh to establish a new 500-bed hospital, marking an expansion of its healthcare services. The company also announced a final dividend recently.

KIMS Hospitals has leased a 2-acre plot in Amaravati for 60 years, with plans to build a 500-bed multi-specialty hospital on the site.

KIMS has formed a strategic partnership with Renova to strengthen their oncology services. The aim is to optimize clinical practices, better patient results, and bolster their reputation in the field.

HSBC has raised its recommendation for Krishna Institute to 'Buy', predicting a target price of ₹780 due to a positive outlook for Q4FY26. This optimism stems from an expected increase in elective procedures, expanded capital expenditure, and the manageable impact of new units on margins.

Krishna Institute recently executed a significant block deal on NSE, worth approximately INR 65.3 crores, for over 9.79 lakh shares. The trade occurred at INR 667 per share.

KIMS Swastha, a subsidiary of Krishna Institute of Medical Sciences, has formed a 20-year partnership with Avitis Super Speciality Hospitals for the growth of medical services in Kerala. The agreement encompasses hospital management, leasing of property, and potential brand extension in Palakkad, Kerala.